secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001213900-24-042338
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q1 net loss $21.2M ($0.61/sh); OLC pivotal topline due Q2 2024
------------------------------------------------------------------------

- Net loss $21.2M ($0.61/sh) vs $14.8M ($0.97) in Q1 2023; R&D expenses rose to $6.8M from $3.0M.
- Cash $48.9M at March 31, 2024; funded operations expected into 2026.
- Topline data from OLC pivotal trial in CKD on dialysis expected in Q2 2024.
- UNI-494 Phase 1 MAD portion ongoing; FDA orphan drug designation for prevention of DGF in kidney transplant.
- Completed $50M private placement with healthcare institutional investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/0001213900-24-042338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/ea0205889-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-042338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer